drugset / Trial / NCT06150898

Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)

NCT06150898

Phase 2 Recruiting 112 enrolled Jules Bordet Institute KU Leuven · collab
RandomizedParallel-groupOpen-labelOther

Summary

Out of all proportion to its short duration, the perioperative period is critical in determining the long-term outcome of cancer. To contribute to a better understanding of the neural and inflammatory mechanisms underlying this issue, we aim to implement a novel intervention based on the preoperative use of non-steroidal anti-inflammatory drugs (NSAIDs) with or without an anti-epileptic drug. Our goal is to understand and transform the perioperative window from being a facilitator of metastatic progression to arresting and/or eliminating residual disease using repurposing drugs

Timeline

Start
2025-05-12
Primary completion
2027-04-20
Completion
2027-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketorolac Other / unclassified 10 mg Oral
Subject Pregabalin Small molecule 75 mg
Background Omeprazole Other / unclassified 20 mg